UNSPSC 51373328: Aspirin/hydrocodone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373328 Aspirin/hydrocodone, a Commodity code, covers pharmaceutical products and related health supplies that state and local governments procure for public health, emergency response, and community health programs. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for harm-reduction initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and direct-to-manufacturer prescription fulfillment capabilities to manage pharmacy benefit costs. The issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing organizations administering contracts on behalf of participating state and local members. Procurements are structured as IFBs (invitation for bids) for direct supply, RFPs for manufacturers entering cooperative agreements, and RFIs (requests for information) for market intelligence on emerging delivery models.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026, response deadline to establish multi-state contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with an effective date of July 1, 2026. Vendors must comply with FDA requirements, Good Manufacturing Practices certification, Drug Supply Chain Security Act standards, and submit pricing in multiple formats including net price, WAC-minus, or fixed-price structures.